Ibandronate Sodium Catalog No.:M8787-2 Proteolysis Targeting Chimeras for the

Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands

GSK269962B

a tyrosine kinase inhibitor

Formula: C59H73N5O10S

Ibandronate Sodium Catalog No.:M8787-2 Proteolysis Targeting Chimeras for theIbandronate sodium is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). Ibandronate is indicated for the treatment and prevention of osteoporosis in post menopausal women. In May 2003, the U. S. Food and Drug Administration (FDA) approved